Regnite launched in July this year, in Japan. We are very excited to see the Astellas' efforts in launching that product, its 1,200 sales reps; they are making a big effort. They estimate about $2 million moderate-to-severe primary RLS patients in Japan, so we'll get our first indication of the sales for the third quarter in the fourth quarter when Astellas presents their financial results. We have a high-teen royalty from sales of the product in Japan.As you know launches in Japan, the prescriptions are limited to 14 days. People have to come back every 14 days in the first year of the launch, so it may take off little slowly, but Astellas has been a great partner for us so far there.
XenoPort's CEO Presents At Morgan Stanley Healthcare Conference (Transcript)
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts